M. Kraus & Co Sells 60 Shares of Amgen Inc. (NASDAQ:AMGN)

M. Kraus & Co lowered its position in Amgen Inc. (NASDAQ:AMGN) by 1.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,569 shares of the medical research company’s stock after selling 60 shares during the quarter. M. Kraus & Co’s holdings in Amgen were worth $1,150,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of AMGN. Sivia Capital Partners LLC lifted its position in shares of Amgen by 7.1% during the 3rd quarter. Sivia Capital Partners LLC now owns 1,321 shares of the medical research company’s stock worth $426,000 after buying an additional 87 shares during the period. Grove Bank & Trust lifted its position in shares of Amgen by 4.1% during the 3rd quarter. Grove Bank & Trust now owns 2,657 shares of the medical research company’s stock worth $856,000 after buying an additional 105 shares during the period. Fiduciary Alliance LLC lifted its position in shares of Amgen by 1.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 26,684 shares of the medical research company’s stock worth $8,598,000 after buying an additional 356 shares during the period. Oxler Private Wealth LLC lifted its position in shares of Amgen by 0.6% during the 3rd quarter. Oxler Private Wealth LLC now owns 9,446 shares of the medical research company’s stock worth $3,044,000 after buying an additional 57 shares during the period. Finally, Stablepoint Partners LLC lifted its position in shares of Amgen by 9.1% during the 3rd quarter. Stablepoint Partners LLC now owns 22,334 shares of the medical research company’s stock worth $7,196,000 after buying an additional 1,860 shares during the period. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMGN. TD Cowen raised their target price on Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $362.00 price objective on shares of Amgen in a research report on Thursday, September 26th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 price objective (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Truist Financial downgraded Amgen from a “buy” rating to a “hold” rating and lifted their price objective for the company from $320.00 to $333.00 in a research report on Monday. Finally, Dbs Bank upgraded Amgen to a “strong-buy” rating in a research report on Monday, September 16th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $326.95.

Amgen Trading Down 0.7 %

NASDAQ:AMGN traded down $2.16 on Monday, reaching $326.19. The company’s stock had a trading volume of 430,323 shares, compared to its average volume of 2,456,504. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The firm has a market cap of $174.98 billion, a PE ratio of 46.91, a PEG ratio of 2.86 and a beta of 0.61. The business’s 50-day moving average price is $326.06 and its two-hundred day moving average price is $310.92.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The firm had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter last year, the firm earned $5.00 earnings per share. Equities research analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a dividend of $2.25 per share. The ex-dividend date was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.76%. Amgen’s payout ratio is presently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.